Cargando…
Fabry Cardiomyopathy: Current Treatment and Future Options
Fabry disease is a multisystem X-linked lysosomal storage disorder caused by a mutation in the alpha-galactosidase A gene. Deficiency or reduced activity of alpha-galactosidase A (GLA) is leading to progressive intracellular accumulation of globotriaosylceramide (GL3) in various organs, including th...
Autores principales: | Vardarli, Irfan, Weber, Manuel, Rischpler, Christoph, Führer, Dagmar, Herrmann, Ken, Weidemann, Frank |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8305771/ https://www.ncbi.nlm.nih.gov/pubmed/34300196 http://dx.doi.org/10.3390/jcm10143026 |
Ejemplares similares
-
Diagnosis and Screening of Patients with Fabry Disease
por: Vardarli, Irfan, et al.
Publicado: (2020) -
Chaperone Therapy in Fabry Disease
por: Weidemann, Frank, et al.
Publicado: (2022) -
Diagnostic accuracy of routine calcitonin measurement for the detection of medullary thyroid carcinoma in the management of patients with nodular thyroid disease: a meta-analysis
por: Vardarli, Irfan, et al.
Publicado: (2021) -
Fabry Cardiomyopathy: Current Practice and Future Directions
por: Yim, Jeffrey, et al.
Publicado: (2021) -
Arrhythmogenic Cardiomyopathy—Current Treatment and Future Options
por: Migliore, Federico, et al.
Publicado: (2021)